ZYMIQ Technology: Year end report 2025
Idag, 08:45
An eventful 2025 and strongly positioned for 2026
During the quarter, ZymIQ carried out strategic recruitment to add important expertise in sales/marketing and Biopharma. These reinforcements are part of building an organization equipped for 2026. At the same time, product development is progressing and a review of the production chain has been initiated to enable future large-scale.
1 jan – 31 dec 2025
- Net sales increased by 48% to SEK 1,902 thousand (1,281)
- Loss after tax amounted to SEK -12,167 thousand (-10,954)
- Earnings per share amounted to SEK -1.39 (–1.04)
- Cash and cash equivalents amounted to SEK 2,488 thousand (3,189)
1 okt – 31 dec 2025
- Net sales amounted to SEK 356 thousand (269)
- Loss after tax amounted to SEK -5,925 thousand (-2,610)
- Earnings per share amounted to SEK -0.67 (–0.31)
Significant events during the reporting period
- ZymIQ receives a positive response from the European Patent Office.
- Emil Bacos has been recruited as Chief Commercial Officer (CCO) of ZymIQ Technology AB starting December 8th.
- ZymIQ has presented its enzyme technology to potential investors at the BioStock Life Science Summit, Lund.
- New agreement between ZymIQ and fjör.
- New cosmetics products have been developed for the Asian market.
Significant events after the reporting period
- Karin Bryder has been recruited as Chief Operating Officer (COO) of the subsidiary ZymIQ Biopharma AB.
- An issue of approximately 519,000 shares was registered with the Swedish Companies Registration Office in January 2026.
For more information, please contact:
Michael Edelborg Christensen, CEO
Phone +46 727 144 166
Email: michael.christensen@zymiq.com
About ZymIQ
ZymIQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymIQ Group. Subsidiaries include ZymIQ Biopharma AB, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymIQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymIQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com
Attachments
Year End Report 2025
ZYMIQ Technology: Year end report 2025
Idag, 08:45
An eventful 2025 and strongly positioned for 2026
During the quarter, ZymIQ carried out strategic recruitment to add important expertise in sales/marketing and Biopharma. These reinforcements are part of building an organization equipped for 2026. At the same time, product development is progressing and a review of the production chain has been initiated to enable future large-scale.
1 jan – 31 dec 2025
- Net sales increased by 48% to SEK 1,902 thousand (1,281)
- Loss after tax amounted to SEK -12,167 thousand (-10,954)
- Earnings per share amounted to SEK -1.39 (–1.04)
- Cash and cash equivalents amounted to SEK 2,488 thousand (3,189)
1 okt – 31 dec 2025
- Net sales amounted to SEK 356 thousand (269)
- Loss after tax amounted to SEK -5,925 thousand (-2,610)
- Earnings per share amounted to SEK -0.67 (–0.31)
Significant events during the reporting period
- ZymIQ receives a positive response from the European Patent Office.
- Emil Bacos has been recruited as Chief Commercial Officer (CCO) of ZymIQ Technology AB starting December 8th.
- ZymIQ has presented its enzyme technology to potential investors at the BioStock Life Science Summit, Lund.
- New agreement between ZymIQ and fjör.
- New cosmetics products have been developed for the Asian market.
Significant events after the reporting period
- Karin Bryder has been recruited as Chief Operating Officer (COO) of the subsidiary ZymIQ Biopharma AB.
- An issue of approximately 519,000 shares was registered with the Swedish Companies Registration Office in January 2026.
For more information, please contact:
Michael Edelborg Christensen, CEO
Phone +46 727 144 166
Email: michael.christensen@zymiq.com
About ZymIQ
ZymIQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymIQ Group. Subsidiaries include ZymIQ Biopharma AB, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymIQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymIQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com
Attachments
Year End Report 2025
Analys
Nya fondtorget
Analys
Nya fondtorget
Marknadsöversikt
1 DAG %
Senast
1 mån
